BioSpace News Archive

Business

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018

A live webcast can be accessed under “Events & Presentations” in the Investors section of the company’s website.

February 1, 2018

·

1 min read

Business

Bavarian Nordic Announces the Planned Departure of CFO, Ole Larsen

The planned transition will take place within 2018 once an appropriate candidate has been identified.

February 1, 2018

·

3 min read

Drug Development

Saniona’s Partner, Medix, Completes Recruitment of Phase III Obesity Study of Tesofensine in Mexico

The trial is expected to be completed in 2018 and topline data is expected by early 2019.

February 1, 2018

·

5 min read

Business

Immutep Limited Announces Milestone Payment From Chinese Partner EOC Pharma

The milestone payment of US$1 million relates to the clinical development of eftilagimod alpha in China and follows the granting of EOC Pharma’s Investigational New Drug (IND) application in China, as outlined in Immutep’s December 12, 2017 Operational Update.

February 1, 2018

·

2 min read

Deals

Sol-Gel Technologies Announces Pricing of IPO

The closing of the initial public offering is expected to occur on or about February 5, 2018, subject to customary closing conditions.

February 1, 2018

·

2 min read

Kane Biotech Announces Trading on the OTCQB Venture Market

With the upgrade to the OTCQB Venture Market, the shares will continue to trade under the ticker symbol “KNBIF.”

February 1, 2018

·

2 min read

Lone Star Bio

Nuvectra Announces Proposed Follow-On Stock Offering

Nuvectra intends to use the net proceeds from this offering to fund the expansion of product development and commercialization activities, as well as for general corporate purposes.

February 1, 2018

·

6 min read

Drug Development

AnaBios Release: Frontiers in Physiology Publishes Research Showing Pro-Arrhythmia Risk Predictivity of Adult Human Primary Ventricular Tissue-Based Model

For this research, human ventricular trabeculae isolated from ethically-consented organ donors were used to assess the effects of 13 blinded clinical reference drugs on cardiac action potential.

February 1, 2018

·

2 min read

Policy

Alnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis

Alnylam announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for patisiran, an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of hereditary ATTR (hATTR) amyloidosis.

February 1, 2018

·

7 min read

ErgoMed Release: Completion of Placing Raising Approximately £3.9 Million for Selected Acquisitions to Augment the Growth of its Services Businesses, Capital Expenditure and Additional Working Capital

ErgoMed of 2,029,971 new Ordinary Shares at 190p per share to raise gross proceeds of approximately £3.9 million.

February 1, 2018

·

3 min read